Remove Communication Remove Events Remove Vaccines
article thumbnail

Pfizer’s COVID-19 vaccine under FDA’s examination following new research into adverse side effects

Pharmafile

The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known severe “adverse events of special interest” (AESIs) which appeared in post-vaccination studies. read more. read more.

article thumbnail

Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication

Pharmaceutical Technology

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The supply chain innovations behind the world’s largest vaccine programme

Pharmaceutical Technology

To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date. In an ever-changing environment, more robust and scalable communications solutions are required.

article thumbnail

Oragenics and Inspirevax sign agreement for Covid-19 vaccine development

Pharmaceutical Technology

Oragenics and Inspirevax have signed a license agreement to develop the former’s lead intranasal vaccine candidate for Covid-19, NT-CoV2-1. As part of the exclusive international agreement, Oragenics agreed to pursue the vaccine development with the new BDX301 intranasal mucosal adjuvant of Inspirevax.

article thumbnail

Scientific evidence ‘on demand’? Proceedings from an expert roundtable

pharmaphorum

The ways in which we communicate and consume information are constantly transforming. In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. Q1: What are some ways in which data dissemination has evolved in 2020?

article thumbnail

10 reasons why virtual collaboration and medical education will persist in the new normal

pharmaphorum

This has been a long time coming and there are countless reasons why I believe virtual collaboration and medical education are here to stay, long after there is a vaccine for COVID-19 and physical distancing guidelines have been lifted. Virtual meetings are not necessarily a replacement for in-person events but rather a supplement”.

article thumbnail

Valuable virtual tools to keep HCPs informed

pharmaphorum

If there’s one take-home message about working during a pandemic, it is the enormous value that virtual events, webinars and e-learning can bring when face-to-face meetings and presentations are impossible. Rewind to March of 2020, and pharma companies were facing a communication crisis. The crisis that changed everything.